Esperion (ESPR)

Company Description

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, once-daily, oral therapies to lower levels of low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is “patient-friendly, physician-friendly, and payer-friendly”.

COMPANY ADDRESS
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108

COMPANY PHONE
734-887-3903

COMPANY WEBSITE



Get BioInvest's perspective on Esperion's CEO


Latest Company News

Technical Indicators for Esperion Therapeutics, Inc. (ESPR) in Short Run StockNewsGazette - 12 hours ago Esperion Therapeutics, Inc. (NASDAQ:ESPR) fell by -6.89% in yesterday's trading from $48.31 to $44.98 and has now fallen 3 consecutive sessions. A Look Ahead For 2 Stocks: Esperion Therapeutics, Inc. (ESPR), Jupai Holdings ... - Post Analyst Institutional Investors Hate on Esperion Therapeutics Inc Falls - BZ Weekly [...]
Fri, Aug 18, 2017 4:41:00 PM, Continue reading at the source
Esperion Therapeutics Inc (ESPR) Relative Momentum Indicator Trending Higher Concord Register - 20 hours ago Drilling into the technicals for Esperion Therapeutics Inc (ESPR), we have noticed that the Relative Momentum Indicator, or RMI, has been trending higher over the past week. What Are The Technicals Telling Us About Esperion Therapeutics Inc (ESPR) - Evergreen Caller [...]
Fri, Aug 18, 2017 9:00:00 AM, Continue reading at the source
Share Activity Lifted for Idera Pharmaceuticals Inc (IDRA) and Esperion ... Evergreen Caller - Aug 17, 2017 Shares of Idera Pharmaceuticals Inc (IDRA) are moving on volatility today -2.84% or $-0.05 from the open. The NASDAQ listed company saw a recent bid of $1.71 and 826357 shares have traded hands in the session. Individual investors may be going to ... [...]
Thu, Aug 17, 2017 9:56:00 PM, Continue reading at the source
Taking a Look Under the Hood at Esperion Therapeutics Inc (ESPR) Shares Melville Review - Aug 16, 2017 Shares of Esperion Therapeutics Inc (ESPR) have seen the needle move -1.93% or -0.87 in the most recent session. The NASDAQ listed company saw a recent bid of 44.11 on 110491 volume. [...]
Wed, Aug 16, 2017 3:22:00 AM, Continue reading at the source
Market Traders Recap -: Esperion Therapeutics, Inc. (ESPR) Hot Stocks Point - Aug 15, 2017 Esperion Therapeutics, Inc. (ESPR) ended its day with loss -1.82% and finalized at the price of $48.43. During its last trading session, Stock traded with the total exchanged volume of 0.8 million shares. Geode Capital Management LLC Buys 7437 Shares of Esperion Therapeutics, Inc ... - BNB Daily (blog) [...]
Tue, Aug 15, 2017 9:45:00 AM, Continue reading at the source
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire (press release) - Aug 11, 2017 ANN ARBOR, Mich., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for ... [...]
Fri, Aug 11, 2017 8:26:00 PM, Continue reading at the source
Esperion Therapeutics (ESPR) Prices 3.1M Share Common Offering at $49/Sh StreetInsider.com - Aug 10, 2017 Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock, offered at a price to the public of $49.00 per share. Esperion Therapeutics, Inc. (ESPR): What's the Story? - StockNewsJournal Esperion Therapeutics, Inc. (ESPR) And Insider Trading Activity - Economic News [...]
Thu, Aug 10, 2017 9:45:00 AM, Continue reading at the source
Here's What's Pushing Up Esperion Therapeutics Inc. Today Motley Fool - Aug 8, 2017 Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR), a clinical-stage biotech focused on reducing cholesterol, popped up again this morning in response to top-line clinical trial results for its lead candidate. Esperion Therapeutics (ESPR) to Offer $150M in Common Stock - StreetInsider.com Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic ... - GlobeNewswire (press release) [...]
Tue, Aug 08, 2017 4:41:00 PM, Continue reading at the source
Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings? August 07, 2017 Zacks.com - Aug 7, 2017 Investors are always looking for stocks that are poised to beat at earnings season and Esperion Therapeutics, Inc. (ESPR - Free Report) may be one such company. [...]
Mon, Aug 07, 2017 12:00:00 PM, Continue reading at the source
Esperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic ... StreetInsider.com - Jul 26, 2017 Esperion Therapeutics, Inc. (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density ... Advaxis, Inc. (ADXS) is at $6.87 per share and Esperion Therapeutics, Inc ... - Stocks Gallery Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Buy ... - Transcript Daily [...]
Wed, Jul 26, 2017 8:42:00 PM, Continue reading at the source